You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH):利奈唑胺片獲藥品註冊證書
格隆匯 06-23 16:51

格隆匯6月23日丨華潤雙鶴(600062.SH)公佈,近日,公司全資子公司華潤賽科藥業有限責任公司(“華潤賽科”)收到了國家藥監局頒發的利奈唑胺片《藥品註冊證書》(證書編號:2021S00703),批准該藥品生產。

該藥品用於治療由特定微生物敏感株引起的:院內獲得性肺炎;社區獲得性肺炎;複雜性皮膚和皮膚軟組織感染,包括未併發骨髓炎的糖尿病足部感染;非複雜性皮膚和皮膚軟組織感染;萬古黴素耐藥的屎腸球菌感染。

截至該公吿日,公司針對該藥品(含製劑和原料藥)累計研發投入為人民幣2156萬元(未經審計)。根據全球71國家藥品銷售數據庫顯示,2020年,利奈唑胺片全球銷售額為2.78億美元。其中,“斯沃”全球銷售額為1.04億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account